Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Allogeneic MSCs in Promoting T-regulatory Cells in Patients With Small Abdominal Aortic Aneurysms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Be 40 and 85 years of age.~* Have diagnosis of noninflammatory degenerative infrarenal abdominal aortic aneurysms measuring 3-5 cm. in diameter by Computed Tomography (CT) scan.~* Females of childbearing potential must be willing to use one form of birth control for the duration of the study. Female participants must undergo a blood or urine pregnancy test at screening.~Exclusion Criteria:~* Inflammatory AAA defined by a thickened aortic wall and retroperitoneal fibrosis and adhesions of peritoneal organs, and elevated erythrocyte sedimentation rate or in the opinion of investigator.~* Mycotic AAA defined as saccular morphology, a positive blood culture, fever, or in the opinion of the investigator.~* Symptomatic, Saccular, or any AAA associated with thoracic aorta dilatation \>5.0 cm.~* Infra-renal AAA associated with Marfan's or Ehlers-Danlos Syndrome or other connective tissue disorders.~* Common or external iliac artery aneurysm \> 30 cm. in maximal transverse diameter.~* AAA due to dissection.~* Allergy to iodine contrast.~* History of cancer within the last 5 years, except basal cell skin carcinoma with clean border pathology report.~* Estimated glomerular filtration rate (eGFR) \< 30mL/min.~* Any condition requiring immunosuppressant medications (e.g., for treatment of organ transplants, psoriasis, Crohn's disease, alopecia areata, rheumatoid arthritis, scleroderma, lupus).~* Acute coronary syndrome (ACS) in the last 30 days prior to enrollment.\*~* Congestive heart failure (CHF) hospitalization within the last 30 days prior to enrollment.\*~* HIV or Hepatitis C (HCV) positive.~* Contraindication to Computed Tomography or known allergy to contrast media.~* Any bleeding diathesis defined as an International Normalized Ratio (INR) 2.0 (off anticoagulation therapy) or history of platelet count less than 70,000 or hemophilia.~* Pregnant or breast-feeding women.~* Significant hepatic dysfunction (alanine transaminase (ALT) or aspartate aminotransferase (AST) greater than 2 times normal).~* Life expectancy less than two years.~* Inability to provide written informed consent due to cognitive or language barriers (interpreter permitted).~* Presence of any clinical condition that in the opinion of the PI or the sponsor makes the patient not suitable to participate in the trial.~  * As defined by the standard definitions of CHF and ACS by the American Heart Association.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Intravenous infusion of 1 million allogenic MSCs/kg (Type: ACTIVE_COMPARATOR): In a randomized fashion, the MSCs, in the appropriate dose, will be shipped to the performance site where the MSCs will be thawed, diluted and administered. The thawed MSCs with be administered within 4 hours to subjects in a monitored setting with telemetry and pulse oximetry. Patients will be premedicated with hydrocortisone and diphenhydramine. All subjects will be monitored throughout the infusion procedure with vital signs and pulse oximetry at 15 minutes prior to infusion and ending 2 hours post procedure. They will also be evaluated for clinical signs of pulmonary distress. Subjects will be discharged 2 hours post-infusion if no signs of complications.
- Intravenous infusion of 3 million allogeneic MSCs/kg (Type: ACTIVE_COMPARATOR): In a randomized fashion, the MSCs, in the appropriate dose, will be shipped to the performance site where the MSCs will be thawed, diluted and administered.The thawed MSCs with be administered within 4 hours to subjects in a monitored setting with telemetry and pulse oximetry. Patients will be premedicated with hydrocortisone and diphenhydramine. All subjects will be monitored throughout the infusion procedure with vital signs and pulse oximetry at 15 minutes prior to infusion and ending 2 hours post procedure. They will also be evaluated for clinical signs of pulmonary distress. Subjects will be discharged 2 hours post-infusion if no signs of complications.
- Intravenous infusion of Plasmalyte A (placebo) (Type: PLACEBO_COMPARATOR): In a randomized fashion, the Plasmalyte A will be shipped to the performance site where it will be thawed and administered. The Plasmalyte A will be administered within 4 hours to subjects in a monitored setting with telemetry and pulse oximetry as will be performed on active groups in order to protect the blinding of this study. Patients will be pre-medicated with hydrocortisone and diphenhydramine. All subjects will be monitored throughout the infusion procedure with vital signs and pulse oximetry at 15 minutes prior to infusion and ending 2 hours post procedure. They will also be evaluated for clinical signs of pulmonary distress. Subjects will be discharged 2 hours post-infusion if no signs of complications.

Based on this trial design, predict the completion outcome and termination type (if applicable).